On the other hand LXRβ-selective agonists are potentially useful to improve cognition in Alzheimer’s disease while avoiding stimulation of hepatic lipogenesis by LXRα, the predominant isoform in the liver56. This evidence concerns the gene NR1H2 and early-onset autosomal dominant Alzheimer disease.